Acrivon Therapeutics appointed Michaela Levin as chief business officer, effective immediately, the clinical-stage biotechnology company said on Monday.
Levin joins Acrivon from Recursion, where she served as vice president of business development and led the acquisition of full rights to the ENPP1 inhibitor REV102 from Rallybio. Prior to Recursion, she held business development roles at Editas Medicine, Ovid Therapeutics and Constellation Pharmaceuticals.
She holds a Ph.D. in neuroscience from the University of Virginia and completed a postdoctoral fellowship in neurobiology at Boston Children’s Hospital and Harvard Medical School.
Acrivon granted Levin 130,000 stock options and 30,000 restricted stock units under its 2023 Inducement Plan. The options vest 25% after one year, with monthly tranches of 2.083%, while the RSUs vest fully after one year. Both awards have a grant date of Sept. 9, with exercise prices equal to the Nasdaq closing price on that date.
Acrivon, based in Watertown, Massachusetts, develops precision medicines using its Generative Phosphoproteomics AP3 platform.
